S12 Ep19: FDA Approval Insights: T-DXd in HER2-Low/-Ultralow Metastatic Breast Cancer: With Aditya Bardia, MD, MPH, FASCO
OncLive® On Air - Un pódcast de OncLive® On Air
Dr Bardia discusses the FDA approval of T-DXd for patients with unresectable or metastatic, hormone receptor–positive, HER2-low/-ultralow breast cancer.
